title: [Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B].
abstract: OBJECTIVE
  To study the relationship between serum load level of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B.
  
  
  METHODS
  Forty-four patients of chronic hepatitis B were divided into two groups, the treated group was treated with oxymatrine 0.4 g/d by intramuscular injection for 3 months, the control group was treated with some liver protecting agents to estimate the therapeutic effect. The serum level of HBV-DNA was determined by quantitative polymerase chain reaction (PCR) before and after treatment.
  
  
  RESULTS
  The seroconversion rate of HBV-DNA and HBeAg in the treated group was 43.47% and 43.47% respectively, which was obviously better than those in the control group respectively (P < 0.05), the quantity of HBV-DNA decreased after treatment from 10(6.83 +/- 1.27) copy/ml to 10(3.35 +/- 3.08) copy/ml. Among them, in patient with HBeAg negative conversion, the pretreatment quantity of HBV-DNA was 10(6.30 +/- 1.42) copy/ml, while in those with no HBeAg negative conversion, it was 10(7.23 +/- 1.23) copy/ml, the difference was significant.
  
  
  CONCLUSIONS
  Oxymatrine is effective in treating chronic hepatitis B. The therapeutic effect is better for patients with lower quantity of serum HBV-DNA.
authors.affiliation: Haimen Municipal Epidemic Prevention Station, Jiangsu 226100.
authors.forename: Yan-xi
authors.initials: YX
authors.lastname: Chen
authors.forename: Bai-yuan
authors.initials: BY
authors.lastname: Mao
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011807:Quinolizines; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D011807:Quinolizines; C037573:oxymatrine; D000093842:Matrines